Drugmaker MSN Group is focussed on introducing generic products for various therapies at a fraction of the innovator’s product price once the patent expires.
“In the next 5-6 years, MSN will bring products, once the patent expires, at one-tenth of the cost,” executive director Bharat Reddy said, announcing that MSN will unveil anti-epilepsy drug Brivanext in India in the next few days.
At ₹15 a tablet, the drug, under the Brivanext brand would be one of the most affordable therapeutic options, he added. While the tablets are expected to be available in pharmacies from February 22, the injectable form will follow. MSN is also planning to unveil the product in the U.S. market.
MSN has developed the active pharmaceutical ingredient and the finished dosage formulation of Brivanext. The product has received approval from the Drugs Controller General of India.
Mr. Reddy said that during 2021, MSN was planning to introduce 16-17 molecules for various therapies, including cardiovascular, oncology, diabetology and CNS. On expansion plans, MSN, which has nine API and five FDF facilities in Hyderabad and the U.S., is constantly expanding facilities.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
